Trial reportLasers in medical science2025
Clinical efficacy of conbercept combined with micropulse laser in patients with polypoidal choroidal vasculopathy.
Trial report in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To evaluate the clinical efficacy of conbercept combined with micropulse laser(MPL) in treating polypoidal choroidal vasculopathy (PCV). In this prospective, randomized controlled trial conducted from February 2023 to April 2024, 52 patients (52eyes) with PCV at Anhui NO.2 Provincial People's hospital were enrolled. Participants were randomized into a conbercept monotherapy group (27cases, 27eyes) and a combination treatment group (conbercept plus micropulse laser(MPL); 25cases, 25eyes). After an initial series of three intravitreal injections, all patients followed the Treat & Extend (T&E) protocol. Aqueous humor samples were collected before each of the first three injections, and cytokines levels were measured after the sample collection. The combined treatment group received a 577 nm MPL application two weeks following the first injection. The best corrected visual acuity (BCVA) 、central macular thickness (CMT) and total macular volume (TMV) of each group were assessed monthly for three months. From the first to the third month post-injection, both treatment groups showed improvements in BCVA and reductions in CMT and TMV, with the combined treatment group demonstrating significantly greater improvements at each monthly evaluation (P < 0.05). Additionally, levels of aqueous humor cytokines, including VEGF-A, IL-5, MCP-1, and Ang-2, were significantly reduced in both groups. Reductions in VEGF-A and MCP-1 concentrations were positively correlated with improvements in BCVA, CMT, and TMV (P < 0.05). Conbercept combined with MPL therapy demonstrates superior clinical efficacy compared to intravitreal injection of Conbercept alone in patients with PCV. Furthermore, changes in VEGF-A and MCP-1 levels may serve as predictive markers for improvements in visual acuity and retinal morphology in these patients.
Indexed as
Identifiers
40976848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.